Skip to main content
  • Meeting abstract
  • Open access
  • Published:

Novel mouse model of steroid-resistant allergic rhinitis by repeated intranasal administration of OVA

Background

Allergic rhinitis (AR) is one of uncontrollable inflammation diseases by a corticosteroid administration. Thus an ideal AR animal model had been required in this research field in order to develop a new effective remedy. We report our establishment of the novel AR animal model resistant to nasal corticosteroid.

Methods

BALB/c mice were sensitized by intraperitoneal injection of ovalbumin (OVA) /ALUM. Two weeks after the sensitization, the mice were administrated OVA intranasally for five times a week (One-week-challenge arm), or five days in the first week followed by three times a week for every two days from the second to the fifth week (Five-week-challenge arm). In the both arms, the day before the first challenge, the mice were randomly divided into four groups (n=8): negative control (NC), vehicle control (VC), mometasone furoate (MF), and dexamethasone (DEX). For the NC groups, sensitized mice were intranasally treated with saline instead of OVA. In the MF groups, 5 μg/10 μL of MF was administrated intranasally 30 minutes before the last OVA challenge. In the DEX groups, 1 mg/kg of DEX was administrated orally 1 hour before the last OVA challenge. The nasal congestion in early phase and late phase responses were measured by two-chambered, double-flow plethysmograph system as specific air way resistance (sRAW) 10 minutes and 3 hours after the last OVA challenge, respectively. The mice were sacrificed by CO2 gas inhalation and the nasal paraffin sections were made for histological evaluation.

Results

In the One-week-challenge arm, the sRAW in MF and DEX group were lower than VC group both in the early (inhibition rates: MF 73%, DEX 94%) and the late phase responses (MF 76%, DEX 84% inhibition). In the Five-weeks-challenge arm, MF and DEX reduced the nasal congestion in the early phase (MF 42%, DEX 58% inhibition), however, the inhibition rate of the late phase was significantly decreased in the MF group (MF 28%, DEX 50% inhibition). The epithelial hyperplasia and the inflammatory cells infiltration were observed in the nasal mucosa, and these grades were more remarkable for Five-week-challenge arm than One-week-challenge arm.

Conclusions

After five weeks OVA challenge, the nasal congestion remained partially even after the nasal corticosteroid treatment. This repeated OVA administration method would provide a quite useful novel disease model to elucidate the mechanisms of nasal steroid-resistant-AR and develop a new remedy.

Author information

Authors and Affiliations

Authors

Rights and permissions

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Izumi, K., Kawasome, H., Azuma, A. et al. Novel mouse model of steroid-resistant allergic rhinitis by repeated intranasal administration of OVA. World Allergy Organ J 8 (Suppl 1), A30 (2015). https://doi.org/10.1186/1939-4551-8-S1-A30

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1186/1939-4551-8-S1-A30